Peregrine Pharmaceuticals | PPHM - Gross Profit On Sales

Peregrine Pharmaceuticals reported $4.15M in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Gross Profit On Sales Change
Agenus AGEN:US USD 20.69M 1.77M
Amgen AMGN:US USD 5.09B 28M
AstraZeneca AZN:LN USD 8.7B 168M
Biocryst Pharmaceuticals BCRX:US USD 77.05M 4.84M
Bristol Myers Squibb BMY:US USD 8.89B 21M
Eli Lilly And LLY:US USD 5.75B 391.2M
GlaxoSmithKline GSK:LN GBP 5.2B 244M
Intrexon XON:US USD 506K 14.64M
Karyopharm Therapeutics KPTI:US USD 31.71M 3.45M
MacroGenics MGNX:US USD 71.31M 32.72M
Mannkind MNKD:US USD 19.93M 4.57M
Merk MRK:US USD 10.47B 610M
Novartis NOVN:VX USD 9.16B 21M
Novavax NVAX:US USD 175.63M 124.35M
Repligen RGEN:US USD 96.06M 18.16M
Roche Holding ROG:VX 22.04B 696M